Fate Therapeutics's top three insider shareholders as of March 23, 2026 are Group, Llc Redmile (Director, 12.88Mn shares), Bahram Valamehr (President And Ceo, 664.71K shares), Cindy Tahl (See Remarks, 487.08K shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Group, Llc Redmile | 0 | 12,884,277 | 26 Dec, 2024 | |
| Bahram Valamehr | President And Ceo | 664,708 | 0 | 16 Jan, 2026 |
| Cindy Tahl | See Remarks | 487,081 | 0 | 16 Jan, 2026 |
| J Scott Wolchko | President And Ceo | 371,248 | 0 | 10 Jan, 2024 |
| Jerome Charles Bressi | See Remarks | 335,203 | 0 | 16 Jan, 2025 |
| John Mendlein | 311,231 | 0 | 20 Jan, 2023 | |
| Yu-Waye Chu | Chief Medical Officer | 140,676 | 0 | 19 Apr, 2023 |
| Yu-Waye Chu | Chief Medical Officer | 140,676 | 0 | 19 Apr, 2023 |
| Mark Plavsic | Chief Technical Officer | 123,705 | 0 | 11 Jan, 2023 |
| Edward J Iii Dulac | Chief Financial Officer | 101,479 | 0 | 05 Mar, 2024 |
| Kamal Adawi | Chief Financial Officer | 100,000 | 0 | 16 Jan, 2026 |
| Brian T. Powl | Chief Commercial Officer | 41,146 | 0 | 06 Jul, 2023 |
| Michael Stewart Lee | 11,331 | 0 | 13 Jun, 2022 | |
| William H Rastetter | 11,331 | 0 | 13 Jun, 2022 | |
| Robert Hershberg | 10,659 | 0 | 13 Jun, 2022 | |
| Shefali Agarwal | 10,490 | 0 | 13 Jun, 2022 | |
| Timothy Coughlin | 9,892 | 0 | 13 Jun, 2022 | |
| Karin Jooss | 9,848 | 0 | 13 Jun, 2022 | |
| Yuan Xu | 8,669 | 0 | 07 Aug, 2024 | |
| Robert S Epstein | 2,681 | 0 | 04 Jun, 2021 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 15 Jan, 2026 | Bahram Valamehr | Common Stock | A | 335,000 | $0.00 | 664,708 | D | A |
| 15 Jan, 2026 | Cindy Tahl | Common Stock | A | 100,000 | $0.00 | 487,081 | D | A |
| 15 Jan, 2026 | Kamal Adawi | Common Stock | A | 25,000 | $0.00 | 100,000 | D | A |
| 15 Jan, 2026 | Bahram Valamehr | Stock Option (Right to Buy) | A | 1,300,000 | $0.00 | 1,300,000 | D | A |
| 15 Jan, 2026 | Cindy Tahl | Stock Option (Right to Buy) | A | 400,000 | $0.00 | 400,000 | D | A |
| 15 Jan, 2026 | Kamal Adawi | Stock Option (Right to Buy) | A | 75,000 | $0.00 | 75,000 | D | A |
| 09 Jan, 2026 | Cindy Tahl | Common Stock | D | 10,589 | $1.06 | 387,081 | D | S |
| 09 Jan, 2026 | Bahram Valamehr | Common Stock | D | 5,190 | $1.07 | 329,708 | D | S |
| 20 Oct, 2025 | Kamal Adawi | Common Stock | A | 75,000 | $0.00 | 75,000 | D | A |
| 20 Oct, 2025 | Kamal Adawi | Stock Option (Right to Buy) | A | 375,000 | $0.00 | 375,000 | D | A |
| 04 Aug, 2025 | Bahram Valamehr | Common Stock | D | 14,466 | $1.06 | 334,898 | D | S |
| 04 Aug, 2025 | Cindy Tahl | Common Stock | D | 9,037 | $1.06 | 397,670 | D | S |
| 29 May, 2025 | John Mendlein | Stock Option (Right to Buy) | A | 55,000 | $0.00 | 55,000 | D | A |
| 29 May, 2025 | Karin Jooss | Stock Option (Right to Buy) | A | 55,000 | $0.00 | 55,000 | D | A |
| 29 May, 2025 | Group, Llc Redmile | Stock Option (Right to Buy) | A | 55,000 | $0.00 | 55,000 | I | A |
| 29 May, 2025 | Michael Stewart Lee | Stock Option (Right to Buy) | A | 55,000 | $0.00 | 55,000 | D | A |
| 29 May, 2025 | Neelufar Mozaffarian | Stock Option (Right to Buy) | A | 55,000 | $0.00 | 55,000 | D | A |
| 29 May, 2025 | Robert S Epstein | Stock Option (Right to Buy) | A | 55,000 | $0.00 | 55,000 | D | A |
| 29 May, 2025 | William H Rastetter | Stock Option (Right to Buy) | A | 55,000 | $0.00 | 55,000 | D | A |
| 29 May, 2025 | Yuan Xu | Stock Option (Right to Buy) | A | 55,000 | $0.00 | 55,000 | D | A |